SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

GameStop Corp. engages in offering games and entertainment products through its ecommerce properties and stores. The firm’s stores and ecommerce sites operate primarily under the names GameStop, EB Games, and Micromania. It operates through the following geographical segments: United States, Canada, Australia, and Europe. The company was founded by Daniel A. DeMatteo in 1996 and is headquartered in Grapevine, TX.

Gamestop Corporation - Ordinary Shares - Class A

GameStop Corp

GameStop is trending following a report that the company is preparing an acquisition bid for eBay, fueling intense community speculation about how a significantly smaller firm could finance such a major deal. Investors are actively debating the potential for a transformative pivot or a complex leveraged buyout, with sentiment split between high-stakes optimism for a massive squeeze and skepticism regarding the feasibility of the acquisition.

$ORDI : first token deployed on Bitcoin Ordinals, with a 21 million supply. $DOGI : first token deployed on Dogecoin Ordinals, with a 21 million supply. The First DRC-20 token in the history

dogi

DOGI is gaining traction as a prominent DRC-20 token on the Dogecoin network, with the community highlighting its ecosystem growth, potential utility from trading bots, and upcoming platform developments. Investors are actively discussing the token's correlation with the broader meme coin market cycle and the rising adoption of Doginals.

Wolfspeed, Inc. is an innovator of wide bandgap semiconductors, focused on silicon carbide and gallium nitride (GaN) materials and devices for power and radiofrequency (RF) applications. Its product families include silicon carbide and GaN materials, power devices and RF devices, and its products are targeted for various applications such as electric vehicles, fast charging, 5G, renewable energy and storage, and aerospace and defense. The company was founded by Calvin H. Carter Jr., John W. Palmour, F. Neal Hunter, Eric Hunter, and John Edmond in 1987 and is headquartered in Durham, NC.

Wolfspeed Inc - Ordinary Shares (New)

Wolfspeed Inc

Wolfspeed is drawing significant investor attention after confirming the receipt of nearly $700 million in federal tax refunds, a cash injection that analysts note exceeds the company's current market capitalization. Community discourse is heavily focused on the stock's potential for a massive short squeeze, with many users highlighting the high short interest and improved balance sheet liquidity as catalysts for a potential rally.

Ginkgo Bioworks Holdings, Inc. engages in developing biological engineering products and custom microbes. Its platform enables biotechnology applications across diverse markets, from food, agriculture, industrial chemicals, and pharmaceuticals. It operates through the Cell Engineering and Biosecurity segments. The Cell Engineering segment includes end-to-end cell engineering solutions and cell engineering tools offerings for biological research and development. The Biosecurity segment focuses on biomonitoring and bioinformatics support services, offered to both government and non-government customers through its Canopy and Horizon offerings. The company was founded by Jason Kelly, Reshma Shetty, Bartholomew Canton, Austin Che, and Thomas F. Knight, Jr. in 2008 and is headquartered in Boston, MA.

Ginkgo Bioworks Holdings Inc - Ordinary Shares - Class A

Ginkgo Bioworks is trending as investors react to reports of an AI-driven autonomous lab milestone achieved using OpenAI technology, which community members are debating as a potential catalyst for long-term platform scalability. While some traders are focused on short-term price volatility and bearish sentiments regarding historical performance, others remain optimistic about the company's long-term infrastructure play in the biotechnology and AI sectors.

Chip

CHIP is seeing intense retail debate as traders weigh potential utility in the AI infrastructure sector against accusations of being a pump-and-dump scheme. The community is sharply divided, with some betting on a short squeeze and long-term holding based on upcoming token unlocks, while others cite high supply dilution and insider selling as reasons for volatility.

Cronos is an institutional-grade, high-performance, EVM-compatible Layer-1 blockchain built on the Cosmos SDK and integrated with the Inter-Blockchain Communication (IBC) protocol, designed as the backbone for open, compliant, and AI-accessible tokenized markets. It supports up to 60,000 transactions per second (TPS), 500ms block times, instant finality, and sub-$0.01 fees via Proof of Authority consensus.

Crypto.com Coin

Cronos ($CRO) is facing intense community skepticism regarding its ongoing token dilution and exchange leadership, even as supporters point to potential catalysts like upcoming Cronos app updates and ETF filings. Meanwhile, the community is actively debating the project's long-term viability against meme coin alternatives and broader market movements.

XPeng, Inc. engages in the design, development, manufacture, and marketing of smart electric vehicles. Its products are environmentally friendly vehicles, namely an SUV (the G3) and a four-door sports sedan (the P7). It also provides a range of services to the clients, including supercharging service, maintenance service, ride-hailing service and vehicle leasing service. The company was founded by Xiao Peng He, Heng Xia, and Tao He in 2015 and is headquartered in Guangzhou, China.

XPeng Inc - ADR

XPeng is seeing active discussion as the community debates its long-term potential in AI and robotics, while the stock faces ongoing pressure from weak delivery data and broader volatility in Chinese EV markets. Traders remain divided, with some betting on a technical turnaround driven by its VLA 2.0 software and strategic partnerships, while others remain cautious due to intensifying competition and shifting macroeconomic headwinds.

Based Chad

CHAD is capturing investor attention through its deflationary flywheel mechanism, active multisig buybacks, and expanding ecosystem that includes upcoming video games and official Base network community integration. The community is heavily focused on the project's supply shock potential and its sustained relative strength, fueled by ongoing endorsements and its status as a widely recognized cultural meme.

DoorDash, Inc. engages in the design, development, and operation of a food delivery and logistics platform. It serves consumers in the United States, Canada, and Australia. The company was founded by Andy Fang, Tony Xu, Stanley Tang, and Evan Moore on January 12, 2013 and is headquartered in San Francisco, CA.

DoorDash Inc - Ordinary Shares - Class A

DoorDash is trending as investors react to a mix of strong Q4 marketplace growth and recent volatility fueled by analyst price target adjustments and debates over the impact of AI-driven delivery disruption. Community sentiment remains polarized, with active discussions focusing on the long-term sustainability of gig economy margins and whether recent analyst downgrades create a potential buying opportunity.

Summit Therapeutics, Inc. is a biopharmaceutical company, that focuses on the discovery, development, and commercialization of patient, physician, caregiver, and societal-friendly medicinal therapies intended to improve quality of life, increase potential duration of life, and resolve serious unmet medical needs. The firm conducts clinical programs focusing on Clostridioides Difficile Infection (CDI). Its lead product, Ridinilazole, is an orally administered small molecule antibiotic that is in Phase III clinical trials for the treatment of CDI. The company was founded in 2003 and is headquartered in Miami, FL.

Summit Therapeutics Inc

Summit Therapeutics is trending as investors actively discuss the company's recent regulatory BLA submission and strategic clinical collaborations while anticipating key updates at upcoming industry conferences. Community sentiment remains focused on the drug's potential to disrupt the lung cancer treatment landscape, with discussions heavily weighing institutional accumulation against ongoing short interest volatility.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Gain Therapeutics, Inc. (NASDAQ:GANX) Receives Consensus Recommendation of "Moderate Buy" from Analysts

Gain Therapeutics, Inc. (NASDAQ:GANX - Get Free Report) has been given a consensus recommendation of "Moderate Buy" by the five research firms that are currently covering the firm, MarketBeat...

HC Wainwright Has Positive Estimate for GANX Q1 Earnings

Gain Therapeutics, Inc. (NASDAQ:GANX - Free Report) - HC Wainwright raised their Q1 2026 earnings estimates for Gain Therapeutics in a research note issued on Monday, March 30th. HC Wainwright...

Gain Therapeutics (NASDAQ:GANX) Issues Earnings Results

Gain Therapeutics (NASDAQ:GANX - Get Free Report) issued its earnings results on Thursday. The company reported ($0.11) EPS for the quarter, beating the consensus estimate of ($0.14) by $0.03...

Gain Therapeutics Highlights GT-02287 Biomarker Signals, Eyes Phase 2 Start in Q3 at Roth Conference

Gain Therapeutics (NASDAQ:GANX) is developing oral small-molecule drugs aimed at neurodegenerative diseases, with its lead focus on Parkinson's disease, company CEO Gene Mack said during a fireside...

Gain Therapeutics (GANX) Expected to Announce Earnings on Thursday

Gain Therapeutics (NASDAQ:GANX) will be releasing its Q4 2025 earnings before the market opens on Thursday, March 26. (View Earnings Report at...

Gain Therapeutics (NASDAQ:GANX) Trading Up 3.7% - What's Next?

Gain Therapeutics (NASDAQ:GANX) Stock Price Up 3.7% - Should You Buy...

Gain Therapeutics, Inc. (NASDAQ:GANX) Receives Consensus Recommendation of "Moderate Buy" from Brokerages

Gain Therapeutics, Inc. (NASDAQ:GANX - Get Free Report) has been assigned a consensus rating of "Moderate Buy" from the seven analysts that are presently covering the firm, Marketbeat reports. One...

Gain Therapeutics, Inc. (NASDAQ:GANX) Short Interest Up 19.9% in January

Gain Therapeutics, Inc. (NASDAQ:GANX - Get Free Report) was the recipient of a significant increase in short interest during the month of January. As of January 30th, there was short interest...

Shares of Gain Therapeutics, Inc. (NASDAQ:GANX - Get Free Report) have been assigned a consensus rating of "Moderate Buy" from the seven brokerages that are currently covering the stock...

Short Interest in Gain Therapeutics, Inc. (NASDAQ:GANX) Rises By 28.6%

Gain Therapeutics, Inc. (NASDAQ:GANX - Get Free Report) was the target of a significant growth in short interest during the month of December. As of December 31st, there was short interest totaling...

Gain Therapeutics, Inc. is a redefining drug discovery company, which identifies and optimizes allosteric binding sites that never targeted before. Its See-Tx target identification platform uses the published 3D structure of enzymes and a proprietary computational technology to discover new allosteric binding sites and predict their druggability. The firm is also unlocking new treatment options to treat disorders characterized by protein misfolding. The company was founded by Khalid Islam in 2017 and is headquartered in Bethesda, MD.

GANX
Gain Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest GANX News

GANXGain Therapeutics Inc